These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 34600548)

  • 1. Characterization of receptor tyrosine kinase activation and biological activity of toceranib phosphate in canine urothelial carcinoma cell lines.
    Korec DI; Louke DS; Breitbach JT; Geisler JA; Husbands BD; Fenger JM
    BMC Vet Res; 2021 Oct; 17(1):320. PubMed ID: 34600548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical analysis of expression of VEGFR2, KIT, PDGFR-β, and CDK4 in canine urothelial carcinoma.
    Setyo LC; Donahoe SL; Shearer PL; Wang P; Krockenberger MB
    J Vet Diagn Invest; 2023 Mar; 35(2):109-115. PubMed ID: 36648148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of receptor tyrosine kinase targets PDGFR-β, VEGFR2 and KIT in canine transitional cell carcinoma.
    Walters L; Martin O; Price J; Sula MM
    Vet Comp Oncol; 2018 Mar; 16(1):E117-E122. PubMed ID: 28884928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of expression and function of vascular endothelial growth factor receptor 2, platelet derived growth factor receptors-alpha and -beta, KIT, and RET in canine apocrine gland anal sac adenocarcinoma and thyroid carcinoma.
    Urie BK; Russell DS; Kisseberth WC; London CA
    BMC Vet Res; 2012 May; 8():67. PubMed ID: 22630170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Toceranib Phosphate in the Treatment of Canine Bladder Tumors: 37 Cases.
    Gustafson TL; Biller B
    J Am Anim Hosp Assoc; 2019; 55(5):243-248. PubMed ID: 31433219
    [No Abstract]   [Full Text] [Related]  

  • 6. Assessment of HER2 Expression in Canine Urothelial Carcinoma of the Urinary Bladder.
    Tsuboi M; Sakai K; Maeda S; Chambers JK; Yonezawa T; Matsuki N; Uchida K; Nakayama H
    Vet Pathol; 2019 May; 56(3):369-376. PubMed ID: 30612533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PDGFR-α, PDGFR-β, VEGFR-2 and CD117 expression in canine mammary tumours and evaluation of the in vitro effects of toceranib phosphate in neoplastic mammary cell lines.
    Gattino F; Maniscalco L; Iussich S; Biasato I; Martano M; Morello E; Gola C; Millán Ruiz Y; Saeki N; Buracco P; Martín de Las Mulas J; De Maria R
    Vet Rec; 2018 Aug; 183(7):221. PubMed ID: 29440590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor.
    Halsey CH; Gustafson DL; Rose BJ; Wolf-Ringwall A; Burnett RC; Duval DL; Avery AC; Thamm DH
    BMC Vet Res; 2014 May; 10():105. PubMed ID: 24885200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation and function of receptor tyrosine kinases in human clear cell renal cell carcinomas.
    Zhang Q; Liu JH; Liu JL; Qi CT; Yan L; Chen Y; Yu Q
    BMC Cancer; 2019 Nov; 19(1):1044. PubMed ID: 31690270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receptor tyrosine kinase expression and phosphorylation in canine nasal carcinoma.
    Hocker SE; Higginbotham ML; Schermerhorn T; Henningson J
    Res Vet Sci; 2017 Dec; 115():484-489. PubMed ID: 28783596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo effects of toceranib phosphate on canine osteosarcoma cell lines and xenograft orthotopic models.
    Sánchez-Céspedes R; Accornero P; Miretti S; Martignani E; Gattino F; Maniscalco L; Gola C; Iussich S; Martano M; Morello E; Buracco P; Aresu L; Maria R
    Vet Comp Oncol; 2020 Mar; 18(1):117-127. PubMed ID: 31816142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of lymphocyte-specific programmed cell death protein 1 receptor expression and cytokines in blood and urine in canine urothelial carcinoma patients.
    Pinard CJ; Stegelmeier AA; Bridle BW; Mutsaers AJ; Wood RD; Wood GA; Woods JP; Hocker SE
    Vet Comp Oncol; 2022 Jun; 20(2):427-436. PubMed ID: 34797014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.
    London CA; Malpas PB; Wood-Follis SL; Boucher JF; Rusk AW; Rosenberg MP; Henry CJ; Mitchener KL; Klein MK; Hintermeister JG; Bergman PJ; Couto GC; Mauldin GN; Michels GM
    Clin Cancer Res; 2009 Jun; 15(11):3856-65. PubMed ID: 19470739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor Tyrosine Kinase Expression Profiles in Canine Cutaneous and Subcutaneous Mast Cell Tumors.
    Thompson JJ; Morrison JA; Pearl DL; Boston SE; Wood GA; Foster RA; Coomber BL
    Vet Pathol; 2016 May; 53(3):545-58. PubMed ID: 26459517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of toceranib phosphate (Palladia) monotherapy on multidrug resistant lymphoma in dogs.
    Yamazaki H; Miura N; Lai YC; Takahashi M; Goto-Koshino Y; Yasuyuki M; Nakaichi M; Tsujimoto H; Setoguchi A; Endo Y
    J Vet Med Sci; 2017 Jul; 79(7):1225-1229. PubMed ID: 28592719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer.
    Cronise KE; Hernandez BG; Gustafson DL; Duval DL
    Mol Pharmacol; 2019 Jul; 96(1):36-46. PubMed ID: 31048548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-tumour effect of lapatinib in canine transitional cell carcinoma cell lines.
    Sakai K; Maeda S; Saeki K; Nakagawa T; Murakami M; Endo Y; Yonezawa T; Kadosawa T; Mori T; Nishimura R; Matsuki N
    Vet Comp Oncol; 2018 Dec; 16(4):642-649. PubMed ID: 30246405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway.
    Yeramian A; Sorolla A; Velasco A; Santacana M; Dolcet X; Valls J; Abal L; Moreno S; Egido R; Casanova JM; Puig S; Vilella R; Llombart-Cussac A; Matias-Guiu X; Martí RM
    Int J Cancer; 2012 Feb; 130(4):967-78. PubMed ID: 21445974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A canine case of malignant melanoma carrying a KIT c.1725_1733del mutation treated with toceranib: a case report and in vitro analysis.
    Tani H; Miyamoto R; Noguchi S; Kurita S; Nagashima T; Michishita M; Yayoshi N; Tamura K; Bonkobara M
    BMC Vet Res; 2021 Apr; 17(1):147. PubMed ID: 33827546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment and characterization of urothelial carcinoma cell lines with and without BRAF mutation (V595E) in dogs.
    Yamasaki H; Uematsu Y; Okano K; Ichikawa M; Tei M; Hirabayashi M; Uchida K; Ono K; Hirao H
    In Vitro Cell Dev Biol Anim; 2022 Dec; 58(10):898-911. PubMed ID: 36477686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.